First Wave BioPharma (FWBI) Stock Price, News & Analysis

Company Overview

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Key Stats

• Today's Range: N/A
• 50-Day Range: $2.60 to $4.63
• 52-Week Range: N/A
• Volume: 56,500 shs
• Average Volume: 212,944 shs
• Market Capitalization: $7.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FWBI Stock Analysis - Frequently Asked Questions

How were First Wave BioPharma's earnings last quarter?

First Wave BioPharma, Inc. (NASDAQ:FWBI) announced its quarterly earnings results on Sunday, November, 14th. The company reported ($13,734.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3,318.00) by $10,416.00.

When did First Wave BioPharma's stock split?

Shares of First Wave BioPharma reverse split before market open on Monday, December 18th 2023.The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of First Wave BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that First Wave BioPharma investors own include Tesla (TSLA), HIVE Digital Technologies (HIVE), BIOLASE (BIOL), Meta Platforms (META) and PayPal (PYPL).

Company Calendar

• Last Earnings: 11/14/2021
• Today: 10/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FWBI
• CIK: 1604191
• Web: www.azurrx.com
• Phone: (561) 589-7020
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.80 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -102.83%
• Return on Assets: -22.74%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 1.21
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.54 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,480,000
• Free Float: 2,463,000
• Market Cap: $7.34 million
• Optionable: Not Optionable
• Beta: 1.28